NCT04148183View on ClinicalTrials.gov

Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2004

Primary Completion Date

January 1, 2005

Study Completion Date

January 1, 2009

Conditions
Insulin Resistance
Interventions
DRUG

Metformin group

We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks

DRUG

Rosiglitazone group

we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks

DRUG

Placebo oral tablet

We add Placebo, treatment was administered for 8 weeks

All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

collaborator

National Council of Science and Technology, Mexico

OTHER

lead

J JESUS VENEGAS, MD

OTHER

NCT04148183 - Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients. | Biotech Hunter | Biotech Hunter